This inventor holds 6 USPTO granted patents and 5 published patent applications and 5 EPO patents. Top assignees: Lonza Inc., Lonza Guangzhou Nansha Ltd., Astrazeneca Ab. Active years: 2010-2023.
Company Filing History:
4 out of 612 
2 out of 2 
1 out of 1,531 
Years Active: 2010-2023
Title: Laurent Ducry: Innovator in Antibody Engineering
Introduction
Laurent Ducry is a prominent inventor based in Sierre, Switzerland. He has made significant contributions to the field of antibody engineering, holding a total of 6 patents. His work focuses on the development of antibodies with modified constant regions, which are crucial for drug conjugation.
Latest Patents
One of Laurent Ducry's latest patents involves CL and/or CH1 mutated antibodies for drug conjugation. These antibodies have modified constant regions that allow for the conjugation of the antibody to a therapeutic payload. The preferred antibodies include a mutation at light chain position 180, with the most favorable mutations being to residues such as C, K, Q, or even non-natural amino acids. Additionally, other mutations can be combined with the mutation at position 180, including various positions on both the light and heavy chains.
Career Highlights
Throughout his career, Laurent Ducry has worked with notable companies such as Lonza Inc. and Lonza Guangzhou Nansha Ltd. His expertise in antibody engineering has positioned him as a key player in the biotechnology industry.
Collaborations
Laurent has collaborated with esteemed colleagues, including Ramon Gomez De La Cuesta and Jesús Zurdo. These collaborations have further enhanced his research and development efforts in the field of antibody technology.
Conclusion
Laurent Ducry's innovative work in antibody engineering has led to significant advancements in drug conjugation technologies. His contributions continue to impact the biotechnology sector positively.